0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
Hypoparathyroidism - Pipeline Insight, 2025 - Product Thumbnail Image

Hypoparathyroidism - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
EUR$1,500USDGBP
Osteoporosis - Pipeline Insight, 2025 - Product Thumbnail Image

Osteoporosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
EUR$2,000USDGBP
Prader Willi Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Prader Willi Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
EUR$1,500USDGBP
Prediabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Prediabetes - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
EUR$1,500USDGBP
Xlinked Hypophosphatemia (XLH) - Pipeline Insight, 2025 - Product Thumbnail Image

Xlinked Hypophosphatemia (XLH) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
EUR$2,000USDGBP
Severe Hypertriglyceridemia - Pipeline Insight, 2025 - Product Thumbnail Image

Severe Hypertriglyceridemia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 70 Pages
  • Global
From
EUR$1,500USDGBP
Severe Hypoglycemia - Pipeline Insight, 2025 - Product Thumbnail Image

Severe Hypoglycemia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
EUR$2,000USDGBP
Metabolic Acidosis - Pipeline Insight, 2025 - Product Thumbnail Image

Metabolic Acidosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
EUR$1,250USDGBP
Adenosine Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Adenosine Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
EUR$2,000USDGBP
Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2025 - Product Thumbnail Image

Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
EUR$1,500USDGBP
Dementia With Diabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Dementia With Diabetes - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
EUR$1,250USDGBP
Chronic Pancreatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Pancreatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
EUR$1,250USDGBP
Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2025 - Product Thumbnail Image

Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
EUR$1,250USDGBP
Diabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetes - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 450 Pages
  • Global
From
EUR$5,000USDGBP
Adult Growth Hormone Deficiency (AGHD) - Pipeline Insight, 2025 - Product Thumbnail Image

Adult Growth Hormone Deficiency (AGHD) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
EUR$2,000USDGBP
Pediatric Growth Hormone Deficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Pediatric Growth Hormone Deficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
EUR$1,250USDGBP
Gout - Pipeline Insight, 2025 - Product Thumbnail Image

Gout - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
EUR$2,000USDGBP
Adult-onset Growth Hormone Deficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Adult-onset Growth Hormone Deficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
EUR$1,250USDGBP
Diabetic Cardiomyopathy - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Cardiomyopathy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
EUR$1,250USDGBP
SMO Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

SMO Protein Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
EUR$1,500USDGBP
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more